The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis

Efthimios Dardiotis, Athina Maria Aloizou, Vasileios Siokas, George P. Patrinos, Georgia Deretzi, Panayiotis Mitsias, Michael Aschner, Aristidis Tsatsakis

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.

Original languageEnglish (US)
Pages (from-to)617-628
Number of pages12
JournalJournal of Molecular Neuroscience
Issue number4
StatePublished - Dec 2018


  • Amyotrophic lateral sclerosis
  • Biomarker
  • Epigenetics
  • MicroRNA
  • Neurodegeneration

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience


Dive into the research topics of 'The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis'. Together they form a unique fingerprint.

Cite this